ZEITSCHRIFT FUR RHEUMATOLOGIE, published by Springer Heidelberg, serves as a vital platform in the field of rheumatology, providing researchers, clinicians, and students with cutting-edge findings and discussions related to the diagnosis, treatment, and management of rheumatic diseases. Since its inception in 1974 and continuing until 2024, this journal retains its commitment to disseminating significant scientific work within this specialized domain. Although it is currently categorized in the Q4 quartile for Rheumatology and ranks 47 out of 73 in Scopus, reflecting its burgeoning presence, the journal is dedicated to evolving and gaining prominence in the academic community. By offering valuable insights and fostering scholarly discourse, ZEITSCHRIFT FUR RHEUMATOLOGIE plays a crucial role in advancing rheumatology research and enhancing patient care practices worldwide. The journal presents an opportunity for its readers to engage with contemporary studies and enrich their understanding of rheumatic ailments.

Journal of Rheumatic Diseases, published by the Korean College of Rheumatology, stands as a pivotal platform in the field of rheumatology, contributing significantly to the advancement of knowledge and clinical practice since its inception. With an impact factor reflecting its esteemed position in the academic community, this open-access journal promotes accessibility to high-quality research, ensuring that groundbreaking discoveries are reachable to all stakeholders in the realm of rheumatic diseases. The journal has maintained its commitment to quality, evidenced by its ranking in the Q3 category for Rheumatology in 2023, and its presence among the top quartiles of medical research. Focusing on innovative therapeutic approaches, emerging diagnostic techniques, and comprehensive reviews, the Journal of Rheumatic Diseases seeks to foster collaboration and dialogue among researchers, clinicians, and students alike. For accessibility, the journal offers numerous articles since its transition to open access in 2017, thereby facilitating research dissemination across the globe. As it converges over the years from 2019 to 2024, the journal promises to be instrumental in shaping the future of rheumatic disease research, inviting contributions that inspire new frontiers in this essential field.

Reumatismo is a distinguished Open Access journal dedicated to the field of rheumatology, published by PAGEPRESS PUBL since 2001. With a rich history dating back to 1952, this journal has been pivotal in disseminating vital research on rheumatic diseases and related disorders. Based in Italy, Reumatismo has earned a reputation for its quality and relevance, achieving a Q3 category ranking in the 2023 Scopus metrics for Rheumatology, reflecting its significant contributions to the field. The journal is committed to providing a platform for the latest scientific developments and clinical innovations, thus aiding researchers, healthcare professionals, and students striving to enhance understanding and treatment of rheumatic conditions. For those seeking to access comprehensive research articles and studies, Reumatismo boasts an open access policy, ensuring that knowledge is freely available to all, fostering collaboration and advancement in rheumatology worldwide.

BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, published by Elsevier, stands as a premier journal in the field of rheumatology, holding a prestigious Q1 ranking in both Medicine (miscellaneous) and Rheumatology categories as of 2023. With an ISSN of 1521-6942 and an E-ISSN of 1521-1770, the journal is dedicated to advancing clinical knowledge and practice through the dissemination of high-quality, peer-reviewed research. Since its inception in 1995, this journal has provided a platform for researchers, clinicians, and healthcare providers to share significant advancements, best practices, and innovative insights that shape the standards of care in rheumatology. The commitment to open access publishing reflects its mission to broaden the reach of critical research findings, ensuring that professionals across the globe can access valuable information in this vital field. The journal's impressive Scopus ranking, positioned at #10 out of 73 in Medicine-Rheumatology, alongside its notable impact factor, underscores its importance and influence in guiding clinical practice and policy in rheumatologic conditions. By engaging with this journal, readers can stay informed about emerging trends and evidence-based strategies that are crucial for improving patient outcomes.

Rheumatology International, published by Springer Heidelberg, is a prestigious journal that focuses on innovative research in the field of rheumatology and immunology. Established in 1981, this peer-reviewed journal has contributed significantly to advancing our understanding of autoimmune disorders, clinical approaches, and therapeutic interventions. It holds a commendable Q2 ranking in the categories of Immunology, Immunology and Allergy, and Rheumatology as of 2023, showcasing its influence and importance within these disciplines. With a robust Scopus ranking—positioned 14 out of 73 in Medicine Rheumatology—it caters to a diverse audience of researchers, clinicians, and students committed to improving patient care and treatment modalities. Although it does not currently offer open access options, the journal remains a vital resource for insights on contemporary challenges and breakthroughs in rheumatological research, published from its base in Heidelberg, Germany.

Reumatologia is a dedicated open-access journal published by TERMEDIA PUBLISHING HOUSE LTD that has been serving the global scientific community since 2005. The journal focuses on the fields of Rheumatology, Immunology, and Allergy, providing a rich platform for researchers and practitioners to share innovative findings, clinical insights, and methodologies. With its roots tracing back to the early 1960s and a steady convergence of quality content through 2024, Reumatologia has secured a place in the academic landscape, currently holding a Q4 rating in Immunology and a Q3 rating in both Immunology and Allergy and Rheumatology categories for 2023. While the journal ranks #42 out of 73 in the Medicine - Rheumatology category, its open-access model ensures that research is widely disseminated, enhancing visibility and accessibility to vital knowledge that shapes therapeutic practices. Located in Poznan, Poland, Reumatologia remains a pivotal source of credible research, fostering collaboration among academics, healthcare professionals, and students internationally.

RHEUMATOLOGY, published by Oxford University Press, is a leading journal in the fields of Pharmacology and Rheumatology, recognized for its significant contribution to advancing the understanding and treatment of rheumatic diseases. With an impressive impact factor and ranking within the top quartiles for both medical pharmacology and rheumatology, this journal serves as an essential resource for researchers, clinicians, and healthcare professionals. The journal spans an extensive publication history, with contributions from 1952 to 1995 and from 1998 to 2024, reflecting its enduring commitment to disseminating high-quality research. The Open Access option allows for broader dissemination of knowledge, enhancing the visibility of groundbreaking studies. Positioned in the United Kingdom, RHEUMATOLOGY not only offers valuable insights into the latest therapeutic advancements and clinical guidelines but also fosters collaboration across disciplines, ensuring that practitioners stay at the forefront of innovation in the management of rheumatic conditions.

CLINICAL AND EXPERIMENTAL RHEUMATOLOGY is a prestigious journal published by CLINICAL & EXPER RHEUMATOLOGY, dedicated to advancing the field of rheumatology and immunology. With a rich history dating back to 1983, the journal serves as a critical platform for researchers, clinicians, and professionals seeking to disseminate and discuss innovative findings in these rapidly evolving areas. Featuring an impressive Q2 ranking in both Immunology and Allergy, as well as Rheumatology, this journal is recognized for its high-quality contributions, placing it among the top tier of academic publications. Operating without an open access model, CLINICAL AND EXPERIMENTAL RHEUMATOLOGY is headquartered in Pisa, Italy, and publishes articles that undergo rigorous peer review to ensure excellence in research. This journal is an invaluable resource for those dedicated to improving patient outcomes through evidence-based practice in rheumatology, immunology, and related fields.

Pediatric Rheumatology is a leading peer-reviewed open access journal published by BMC, dedicated to disseminating high-quality research in the field of pediatric rheumatology. Since its inception in 2007, the journal has established itself as a vital resource for healthcare professionals, researchers, and students focused on pediatric immunology, rheumatology, and child health, maintaining an impressive Q1 ranking in Pediatrics and Q2 in Immunology and Allergy as well as Rheumatology for 2023. It is recognized for its impact on advancing knowledge and clinical practice, with significant contributions noted in various studies and case reports. With access options that embrace the ethos of open science, all articles published in Pediatric Rheumatology are freely available, promoting collaborative research and discussion among practitioners across the globe. The journal welcomes submissions that encapsulate innovative research, clinical trials, and reviews that address both current challenges and advancements within the pediatric rheumatology landscape.

Open Access Rheumatology-Research and Reviews, published by DOVE MEDICAL PRESS LTD, is a distinguished journal that has been a vital part of the rheumatology field since its inception in 2009. With an ISSN of 1179-156X, this journal is dedicated to disseminating groundbreaking research and comprehensive reviews in the discipline of rheumatology, making it an essential resource for researchers, clinicians, and students alike. It boasts an impressive Q3 ranking in the Rheumatology category for 2023, reflecting its relevance and quality within a highly competitive landscape, where it ranks in the 51st percentile among its peers as indicated by the Scopus Ranks. As an open-access platform, it ensures that critical findings and insights are easily accessible to a global audience, promoting collaboration and knowledge sharing. The journal's scope includes a wide range of topics within rheumatology, aimed at advancing understanding and treatment of musculoskeletal disorders and autoimmune diseases. Its headquarters is located in New Zealand, positioning it as a key player in the international research community.